Analysis Of The Latest Advances In AIDS Treatment

The development of an AIDS vaccine is an important task and challenge facing the world. Although HIV has been discovered for more than 30 years, due to its variability and diversity, no vaccine against AIDS has yet been put into use. But the search for the ultimate treatment of HIV is still ongoing, and advances in AIDS treatment are continuing.

New AIDS drug candidate emerges

In a finding about advances in AIDS treatment published in the British journal "Nature", a team of American scientists reported a new long-acting antiretroviral drug, showing the potential to treat human immunodeficiency virus infection. Preliminary clinical studies have shown that HIV-infected people experienced a reduction in viral load after a single dose of the drug, and the drug remained active in the body more than six months after the injection. At present, the treatment of AIDS for all human beings mainly relies on high-efficiency antiretroviral therapy. HIV is a retrovirus, and its reverse transcription process is completed under the action of viral reverse transcriptase. And human antiretroviral therapy, it is HIV infection from a fatal disease into a manageable chronic disease. However, this also means that AIDS patients need to inject drugs every day, become dependent on them, and may lead to the development of drug-resistant HIV, which seriously weakens the treatment effect. Research suggests that new long-acting drugs are needed to give those patients with drug-resistant HIV strains more treatment options and help patients stick to their treatment regimens.

"GS-6207" becomes ideal supplement for combination therapy

California-based Gilead has developed a small molecule called "GS-6207" that destroys the HIV "capsid", the protein coat that wraps the viral genome. Building on past research, the researchers engineered "GS-6207" to bind tightly to viral capsid proteins, thereby interfering with viral replication. The research team found that in experiments, "GS-6207" showed potent activity against multiple HIV strains and synergized with approved antiretroviral drugs, making it an ideal addition to combination therapy. According to a clinical study involving 40 healthy individuals, "GS-6207" administered by injection was overall safe, well tolerated, and remained active in the body more than 6 months after injection. Most small-molecule antiretroviral drugs used to treat HIV work by interfering with viral enzymes, but this latest discovery supports targeting the viral capsid protein to treat HIV infection. The small molecule, which does not require frequent dosing, has the potential to be a candidate for preventing HIV infection in at-risk groups, the researchers say, which needs to be tested in future studies.

Most powerful latent reversal method to date improves HIV clearance odds

A new animal study published in the British journal "Nature" shows that scientists using two methods to reverse the latent HIV virus will improve the chances of clearing the virus. This method of "activating" the hidden virus is the most powerful method of latent reversal to date, and it opens a new door for the medical community to further understand the mechanism of virus reversal maintenance. AIDS is a serious infectious disease caused by human immunodeficiency virus, and HIV is a retrovirus. However, current antiretroviral therapy does not completely clear HIV infection because the virus lurks in cells, "hiding" from the immune system in this way. Therefore, clearing HIV infection after long-term viral suppression therapy has been a focus of research. According to the "shock and kill" method devised by the scientists, the virus is first driven out of latent infected cells and then cleared. This approach significantly and persistently activated the virus in all treated animals.

Recent advances in AIDS treatment - dapivirine vaginal ring

The World Health Organization (WHO) recommends dapivirine vaginal ring (DPV-VR) as a preventive strategy in patients at significant risk of infection as part of a combined preventive approach. DPV-VR can reduce the risk of contracting HIV. In order to use a vaginal ring properly, it must be worn inside the vagina for 28 days before a new vaginal ring is put on. The vaginal ring is made of silicone and is easy to bend and insert. The ring works by slowly releasing the antiretroviral drug dapivirine from the vaginal ring into the vagina over 28 days.

Conclusion

The above is a detailed introduction to the advances in AIDS treatment. According to the existing medical research, there may be effective drugs for AIDS in the next few years. The current HIV antiretroviral drugs have made great progress. If the experimental data is ideal, it may be launched to the market. So there is great hope for a complete cure for AIDS in the future.